Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.

de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, Tavan D, Petit-Laurent F, Rivoire M, Pérol D, Carrie C.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):409-13. doi: 10.1016/j.ijrobp.2009.05.008. Epub 2010 Jan 29.

PMID:
20116933
2.

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.

Takeda K, Negoro S, Kudoh S, Okishio K, Masuda N, Takada M, Tanaka M, Nakajima T, Tada T, Fukuoka M.

Br J Cancer. 1999 Mar;79(9-10):1462-7.

3.

Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.

Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):974-81.

PMID:
11704320
4.

A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.

Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, Ghosh C, Keppen MD, Fitch TR, Goldberg RM.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1305-10.

PMID:
12654442
5.
6.

A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.

Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, Shyr Y, Caillouette C, Chakravarthy B.

Radiother Oncol. 2005 Jul;76(1):54-8.

PMID:
15921772
7.

A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71. doi: 10.1016/j.ijrobp.2012.02.051. Epub 2012 Apr 27.

8.

Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer.

Ashamalla H, Zaki B, Mokhtar B, Colella F, Selim H, Krishnamurthy M, Ross P.

Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):679-87. Erratum in: Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1158.

PMID:
12573755
9.

Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer.

Poggi MM, Kroog GS, Russo A, Muir C, Cook J, Smith J, Mitchell JB, Herscher LL.

Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):670-6.

PMID:
12377317
10.

A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.

Malik I, Hussein F, Bush D, Alqaisi M, Bernal P, Byrd J, Garberoglio C.

Am J Clin Oncol. 2010 Jun;33(3):242-5. doi: 10.1097/COC.0b013e3181a650fb.

PMID:
19806036
11.

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.

Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22.

PMID:
11483344
12.

Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.

Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, Levine E, Blackstock AW.

Am J Clin Oncol. 2005 Aug;28(4):345-50.

PMID:
16062075
13.

Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.

Joensuu TK, Kiviluoto T, Kärkkäinen P, Vento P, Kivisaari L, Tenhunen M, Westberg R, Elomaa I.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52.

PMID:
15380578
14.

Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.

Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenes HR.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):284-91. doi: 10.1016/j.ijrobp.2014.02.024. Epub 2014 Apr 11.

PMID:
24726286
16.

Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.

Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, Pond GR, Hedley D, Wong S, Townsley C, Brezden-Masley C, Moore M.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1027-36. Epub 2006 Dec 29.

PMID:
17197132
17.

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.

Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1426-32. doi: 10.1016/j.ijrobp.2009.06.053. Epub 2010 Jan 7.

PMID:
20056351
18.

A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C, Cunningham D.

Ann Oncol. 2003 Aug;14(8):1264-9.

PMID:
12881390
19.

Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.

Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H; Working Group for Pancreas Cancer.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):498-504. doi: 10.1016/j.ijrobp.2015.12.362. Epub 2015 Dec 20.

PMID:
26883565
20.

A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.

Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, Hiraki Y, Nakajo M, Natsugoe S, Takao S.

J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):152-8. doi: 10.1007/s00534-011-0400-y.

PMID:
21647560

Supplemental Content

Support Center